Vortex Biosciences
Venture Round in 2023
Vortex Biosciences, Inc., founded in 2010 and located in Palo Alto, California, specializes in developing liquid biopsy technology for cancer diagnosis and monitoring. The company focuses on oncology diagnostics by integrating cancer biology, microfluidic engineering, and informatics to create advanced tools for isolating and characterizing circulating tumor cells (CTCs). Its flagship product, the VTX-1 Liquid Biopsy System, automates the label-free isolation and collection of viable CTCs from whole blood, eliminating the need for pre-treatment. This system allows healthcare professionals to efficiently collect intact CTCs with high purity in under an hour, ultimately improving therapeutic decisions and outcomes for cancer patients.
Sofant
Venture Round in 2022
Sofant is focused on developing advanced radio-frequency microelectromechanical systems (RF MEMS) technology aimed at addressing power consumption and heat management challenges in high-frequency phased array antenna systems. The company specializes in creating smart antenna solutions for mobile devices and is actively involved in the millimeter-wave market, which includes applications for fifth-generation communications and satellite communications. By integrating its patented technology with innovative antenna designs and machine learning algorithms, Sofant enables organizations to lower costs and simplify the complexities associated with state-of-the-art antenna designs.
Vortex Biosciences
Debt Financing in 2022
Vortex Biosciences, Inc., founded in 2010 and located in Palo Alto, California, specializes in developing liquid biopsy technology for cancer diagnosis and monitoring. The company focuses on oncology diagnostics by integrating cancer biology, microfluidic engineering, and informatics to create advanced tools for isolating and characterizing circulating tumor cells (CTCs). Its flagship product, the VTX-1 Liquid Biopsy System, automates the label-free isolation and collection of viable CTCs from whole blood, eliminating the need for pre-treatment. This system allows healthcare professionals to efficiently collect intact CTCs with high purity in under an hour, ultimately improving therapeutic decisions and outcomes for cancer patients.
Q-Bot
Venture Round in 2022
Q-Bot Limited, founded in 2012 and based in London, specializes in developing robotic tools that operate beneath floors to insulate floorboards. The company has created a robotics platform capable of accessing, surveying, evaluating, and applying treatments across various sectors. Q-Bot's intelligent tools employ artificial intelligence to assess and maintain building health, thereby enhancing building quality and energy efficiency while minimizing risks for workers. By utilizing innovative methods, Q-Bot offers construction professionals a cost-effective and non-disruptive solution for improving home comfort and energy performance. The company is supported by a mix of government grants, private investments, and sales revenue, and has received backing from organizations such as Climate-KIC and The Technology Strategy Board.
Vortex Biosciences
Corporate Round in 2022
Vortex Biosciences, Inc., founded in 2010 and located in Palo Alto, California, specializes in developing liquid biopsy technology for cancer diagnosis and monitoring. The company focuses on oncology diagnostics by integrating cancer biology, microfluidic engineering, and informatics to create advanced tools for isolating and characterizing circulating tumor cells (CTCs). Its flagship product, the VTX-1 Liquid Biopsy System, automates the label-free isolation and collection of viable CTCs from whole blood, eliminating the need for pre-treatment. This system allows healthcare professionals to efficiently collect intact CTCs with high purity in under an hour, ultimately improving therapeutic decisions and outcomes for cancer patients.
Q-Bot
Venture Round in 2021
Q-Bot Limited, founded in 2012 and based in London, specializes in developing robotic tools that operate beneath floors to insulate floorboards. The company has created a robotics platform capable of accessing, surveying, evaluating, and applying treatments across various sectors. Q-Bot's intelligent tools employ artificial intelligence to assess and maintain building health, thereby enhancing building quality and energy efficiency while minimizing risks for workers. By utilizing innovative methods, Q-Bot offers construction professionals a cost-effective and non-disruptive solution for improving home comfort and energy performance. The company is supported by a mix of government grants, private investments, and sales revenue, and has received backing from organizations such as Climate-KIC and The Technology Strategy Board.
EpiBone
Venture Round in 2021
EpiBone, Inc. is a biotechnology company based in Brooklyn, New York, focused on developing advanced solutions for bone and cartilage repair. Founded in 2013, EpiBone utilizes patient-specific scans and their own stem cells to create customized bone grafts, which are cultivated in a bioreactor to facilitate growth. The company aims to improve skeletal repair and enhance bone formation and regeneration through its innovative technologies. EpiBone's lead product, a living 3D bone graft, successfully completed its Phase I/IIa clinical trial in August 2023. Additionally, the company is advancing its cartilage repair pipeline, which includes an allogeneic osteochondral plug that received Investigational New Drug approval in July 2023, and an injectable cartilage filler, partly funded by the Department of Defense. Through these developments, EpiBone seeks to revolutionize orthopedic repair and provide patients with more effective treatment options.
Sofant
Venture Round in 2021
Sofant is focused on developing advanced radio-frequency microelectromechanical systems (RF MEMS) technology aimed at addressing power consumption and heat management challenges in high-frequency phased array antenna systems. The company specializes in creating smart antenna solutions for mobile devices and is actively involved in the millimeter-wave market, which includes applications for fifth-generation communications and satellite communications. By integrating its patented technology with innovative antenna designs and machine learning algorithms, Sofant enables organizations to lower costs and simplify the complexities associated with state-of-the-art antenna designs.
PointGrab
Venture Round in 2021
PointGrab Ltd. specializes in machine learning technology for optical IoT devices designed for home and building automation. Founded in 2008 and based in Hod Hasharon, Israel, the company offers solutions such as PointSwitch, an optical module that transforms visual signals into actionable analytics. This technology provides essential features like occupancy sensing, ambient light detection, and behavioral analytics, enabling businesses to optimize real estate management, enhance efficiency, and reduce costs while ensuring employee privacy and welfare. PointGrab is recognized as a leader in the commercial real estate sector, integrating its optical sensors with connected systems for lighting, HVAC, safety, security, and access control, thereby delivering comprehensive insights into occupant usage within buildings.
SageTech Medical
Seed Round in 2021
SageTech Medical Equipment specializes in the development of anesthetic technology for both human and veterinary healthcare providers. Founded in 2015 and based in Paignton, United Kingdom, the company has created a patented process that captures, extracts, and purifies inhalational anesthetic agents. This innovative approach not only offers significant cost savings but also addresses environmental concerns associated with anesthetic waste. SageTech's systems are designed to operate on both industrial and compact scales, allowing for bulk capture in larger settings as well as integration into anesthetic machines for recycling in clinical environments. By promoting a circular economy for anesthetic agents, SageTech provides a sustainable solution that benefits healthcare providers and the environment alike.
ProAxsis
Acquisition in 2020
ProAxsis Ltd. focuses on developing laboratory-based immunoassays and rapid point-of-care tests for capturing, detecting, and measuring active protease biomarkers associated with various diseases. The company utilizes patented "ProteaseTags®," which are designed to trap active proteases within complex biological samples, allowing for a visual readout of their presence. This technology has been validated for several active protease species as biomarkers in fields such as cancer, infections, and respiratory diseases like bronchiectasis, cystic fibrosis, and COPD. ProAxsis's first immunoassay, which measures active neutrophil elastase as a biomarker for lung infection and inflammation, received a European CE Mark in 2016. The company’s products aim to enhance diagnostic capabilities for healthcare professionals, facilitating immediate results in clinical or home settings.
EMV Capital
Acquisition in 2020
EMV Capital Ltd is a venture capital firm founded in 2018 and based in London, United Kingdom. The firm specializes in early-stage, high-growth deep tech companies, focusing on sectors such as life sciences, sustainability, and industrials. EMV Capital is dedicated to incubating and investing in companies at various stages, including seed, pre-Series A, Series A, and growth phases, while avoiding investments in apps, digital media, B2C companies, and unproven technologies. The firm seeks opportunities in healthcare, energy, transport, the circular economy, smart cities, robotics, AI, and other advanced technology sectors, primarily targeting businesses in the UK, US, and Israel. EMV Capital employs unique investment strategies tailored to each portfolio company, leveraging its extensive network of private investors and institutions to facilitate funding and drive transformational growth. It operates as a wholly owned subsidiary of NetScientific plc.
ProAxsis
Seed Round in 2014
ProAxsis Ltd. focuses on developing laboratory-based immunoassays and rapid point-of-care tests for capturing, detecting, and measuring active protease biomarkers associated with various diseases. The company utilizes patented "ProteaseTags®," which are designed to trap active proteases within complex biological samples, allowing for a visual readout of their presence. This technology has been validated for several active protease species as biomarkers in fields such as cancer, infections, and respiratory diseases like bronchiectasis, cystic fibrosis, and COPD. ProAxsis's first immunoassay, which measures active neutrophil elastase as a biomarker for lung infection and inflammation, received a European CE Mark in 2016. The company’s products aim to enhance diagnostic capabilities for healthcare professionals, facilitating immediate results in clinical or home settings.
Nuada is a specialized carbon capture company that focuses on decarbonizing heavy industries through advanced point-source capture technology. The company develops energy-efficient CO2 filtration machines designed to assist industrial emitters in achieving their Net Zero targets. By offering innovative solutions for carbon capture, Nuada aims to reduce the environmental impact of hard-to-abate sectors while maintaining economic viability. This approach positions Nuada as a key player in the transition towards sustainable industrial practices.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.